Abstract
SARS-COV-2 explores every possible vulnerability in human body and uses it against the host. To treat this SARS-COV-2 induced COVID-19, we should consider and target the multiple factors this virus is targeting and identify the drugs for usage in a strategical way. This approach can save the patients from severe state of illness and damage associated with this disease. COVID-19 has been associated with hyper inflammation [101-109] and delayed humoral immune responses [110-115]. Most of the complications with COVID-19 patients have been associated with early hypoxia, ARDS, pneumonia [116-122] and Acute Lung Injury [123-127]. Viral load has been found to be associated directly with incidence of lung injury/epithelial injury or remote organ injury in COVID-19 patients [128-133].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
